Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data

Table 1 Characteristics and utilization of drugs of uncertain medical benefit

Drugs	Approved Indication	Total Days Supply prescribed in 2014^a	Total Drug Cost in 2014^b	Cost/day (Total drug cost/total days’ supply)	AlternativesBrand Alternative Generic Alternative
Altoprev (Lovastatin ER)	Hyperlipidemia	32,954	512,685	15.56	Rosuvastatin (Crestor)
Altoprev (Lovastatin ER)	Hyperlipidemia	32,954	512,685	15.56	Lovastatin
Axert (Almotriptan)	Migraine	20,433	546,958	26.77	Rizatriptan (Maxalt)
Axert (Almotriptan)	Migraine	20,433	546,958	26.77	Sumatriptan
Azor (Amlodipine+Olmesartan)	Hypertension	11,372,402	64,391,400	5.66	Telmisartan (Micardis)
Azor (Amlodipine+Olmesartan)	Hypertension	11,372,402	64,391,400	5.66	Irbesartan
Duexis (Ibuprofen+Famotidine)	Arthritis	76,607	1,994,159	26.03	Celecoxib (Celebrex)
Duexis (Ibuprofen+Famotidine)	Arthritis	76,607	1,994,159	26.03	Ibuprofen
Kombiglyze XR (Saxagliptin+Metformin)	Diabetes	4,191,109	39,075,907	9.32	Sitagliptin (Januvia)
Kombiglyze XR (Saxagliptin+Metformin)	Diabetes	4,191,109	39,075,907	9.32	Metformin
Vimovo (Naproxen+Esomeprazole)	Arthritis	518,280	13,104,735	25.29	Celecoxib (Celebrex)
Vimovo (Naproxen+Esomeprazole)	Arthritis	518,280	13,104,735	25.29	Naproxen

^aTotal days supply for the selected drug in Medicare Provider Utilization and Payment Data: Part D Prescriber Public Use File,
^bTotal cost for the selected drug per Medicare Provider Utilization and Payment Data: Part D Prescriber Public Use File

ISSN: 1472-6963